Tocagen Inc (NASDAQ:TOCA) – Svb Leerink upped their FY2020 earnings estimates for Tocagen in a note issued to investors on Wednesday, May 22nd. Svb Leerink analyst D. Graybosch now forecasts that the company will earn ($0.93) per share for the year, up from their prior estimate of ($0.98). Svb Leerink currently has a “Market Perform” rating and a $11.00 target price on the stock. Svb Leerink also issued estimates for Tocagen’s FY2021 earnings at $0.01 EPS, FY2022 earnings at ($0.30) EPS and FY2023 earnings at ($0.10) EPS.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.74) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.75) by $0.01. Tocagen had a negative net margin of 294.74% and a negative return on equity of 108.08%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $2.01 million.
A number of other research firms have also recently weighed in on TOCA. Zacks Investment Research cut shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 26th. Chardan Capital reiterated a “buy” rating on shares of Tocagen in a research report on Tuesday, April 23rd. ValuEngine cut shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Finally, Leerink Swann started coverage on shares of Tocagen in a research report on Monday, April 15th. They set a “market perform” rating and a $10.26 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Tocagen presently has an average rating of “Buy” and an average price target of $16.75.
TOCA stock opened at $4.59 on Friday. The company has a current ratio of 5.05, a quick ratio of 5.05 and a debt-to-equity ratio of 0.75. Tocagen has a twelve month low of $4.40 and a twelve month high of $15.80. The firm has a market cap of $209.76 million, a price-to-earnings ratio of -1.88 and a beta of 3.29.
A number of large investors have recently added to or reduced their stakes in the stock. Morgan Stanley lifted its position in Tocagen by 237.8% during the first quarter. Morgan Stanley now owns 144,136 shares of the company’s stock worth $1,567,000 after buying an additional 101,472 shares during the period. Oxford Asset Management LLP lifted its position in Tocagen by 23.2% during the first quarter. Oxford Asset Management LLP now owns 188,743 shares of the company’s stock worth $2,052,000 after buying an additional 35,550 shares during the period. Essex Investment Management Co. LLC purchased a new position in Tocagen during the first quarter worth about $905,000. Geode Capital Management LLC lifted its position in Tocagen by 27.3% during the first quarter. Geode Capital Management LLC now owns 269,545 shares of the company’s stock worth $2,929,000 after buying an additional 57,750 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Tocagen by 21.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 47,173 shares of the company’s stock worth $513,000 after buying an additional 8,473 shares during the period. 33.16% of the stock is owned by institutional investors.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
See Also: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.